We have previously shown that all-trans retinoic acid (ATRA) increases the number of CFU-GM colonies grown from unseparated human bone marrow cells with crude sources of colony stimulating factors. In this study, we further characterized the effect of ATRA on the growth of CFU-GM stimulated by individual cytokines from multiple samples of CD34 ؉ enriched or purified human bone marrow cells. The number of IL-3-or GM-CSF-induced CFU-GM with 3 ؋ 10 ؊7 M ATRA was 3.25 ± 1.13, and 2.17 ؎ 0.8-fold greater respectively, compared to controls without ATRA, while G-CSF had no effect and the ratio of colony-induced with or without ATRA was 1.06 ؎ 0.17 (P ‫؍‬ 0.00012). No colonies grew with ATRA ؉ IL-6 or ATRA without a cytokine. Maximum enhancing effect on IL-3-induced CFU-GM occurred when ATRA was added on day 2, gradually diminished when delaying ATRA, and in cultures of day 9 or older adding ATRA had no effect. In 14 days liquid cultures of purified CD34
Introduction
Vitamin A and its derivatives (retinoids) play an important role in embryogenesis as well as the growth, differentiation and regulation of various types of normal and malignant cells [1] [2] [3] [4] including hematopoietic cells. [5] [6] [7] [8] The most established effect of all-trans retinoic acid (ATRA) is its ability to induce differentiation of acute promyelocytic leukemia (APL) cells, both in vitro, 9, 10 and in vivo 11, 12 and is associated with complete hematological remission in almost all patients with APL when used in doses that provide supraphysiological serum concentrations. 13, 14 Of importance, APL is associated with a balanced t (15;17) translocation that rearranges one allele of the gene encoding the retinoic acid receptor alpha (RAR␣) on chromosome 17 with the promyelocytic (PML) gene on chromosome 15 . [15] [16] [17] The translocation is unique for APL and has never been described in other cancers.
It is most likely that the differentiation of APL cells by ATRA is mediated through the APL-specific PML/RAR␣ fusion transcript, [19] [20] [21] [22] but this does not exclude the possibility that normal hematopoietic cells, which have two normal RAR␣ alleles, would also respond to ATRA. Employing murine cells, Tsai and Collins 6 have shown that normal RAR␣ receptor in synergy with GM-CSF, is essential for normal differentiation of myeloid progenitors. In these experiments, the differentiation of normal mouse bone marrow cells by GM-CSF could be blocked at the promyelocytic stage, by transducing the cells with a retroviral vector that harbored a truncated RAR␣ gene (LRAR␣ 403SN), exhibiting dominant negative activity against normal RAR␣. Further, supraphysiological concentrations of ATRA were shown to overcome this block, and together with GM-CSF, induce terminal cellular differentiation. 6 Using human bone marrow mononuclear cells, we reported several years ago that supraphysiological concentrations of ATRA influenced the growth in vitro of normal myeloid progenitor cells, 23 by increasing approximately twofold the number of CFU-GM colonies induced by crude preparations of colony-stimulating factor. This observation was later confirmed by several other groups, using unseparated, [24] [25] [26] [27] more purified hematopoietic progenitors 28 or CD34 + cells. [29] [30] [31] In these reports, crude conditioned medium or a mixture of cytokines was used to stimulate CFU-GM colony growth. Physiologically, low levels (nanomolar range) of ATRA are present in normal plasma. However, pharmacological doses of ATRA have been administered in several clinical trials treating different types of tumors, resulting in higher plasma ATRA levels. Our experiment focuses on the effect in vitro of supraphysiological concentrations (micromolar range) of ATRA, which are the levels attained in the plasma of patients treated with this drug. In our earlier experiments, 23 we grew CFU-GM colonies from a heterogeneous mixture of mononuclear bone marrow cells and used different conditioned media as sources of colony-stimulating factor. In the current study, we used a homogeneous population of CD34 + enriched or purified normal human bone marrow cells and examined the effect of ATRA on CFU-GM growth, stimulated by the individual hematopoietic cytokines IL-3, GM-CSF, G-CSF, or IL-6. The experiments were performed on multiple samples to investigate if the growth-stimulating effect of ATRA on myeloid progenitors is consistent in samples from different individuals. We also examined the effect of ATRA on IL-3-induced myeloid differentiation and apoptosis of CD34 + cells.
Materials and methods

Cytokines and reagents
The following recombinant cytokines were used: IL-3 (Genzyme, Cambridge, MA, USA), GM-CSF (Immunex, Seattle, WA, USA), G-CSF (Amgen, Thousand Oaks, CA, USA) 
Cell purification and phenotype analysis
Bone marrow cells free of tumor were obtained from harvests of patients undergoing autologous transplantation. Mononuclear cells were isolated by Ficoll-Hypaque (Organon; Teknika, Durham, NC, USA) gradient centrifugation. CD34
+ cells were first enriched with an immunoabsorption column (CellPro, Bothel, WA, USA) according to the manufacturer's instructions. Briefly, cells were incubated with biotinylated anti-CD34 antibodies for 25 min at room temperature. After washing, the cells were loaded on an avidin column and the CD34 + cells that bound to the column were eluted by mechanical agitation and washed. The purity of the CD34 + cells isolated by this method was only 55-96%. In order to obtain a higher degree of purification in certain experiments we used a second step of flow cytometric separation. Because of the requirement for large numbers of CD34 + cells and the very long time required to isolate them by flow cytometry, the twostep purification was not performed in all the experiments. Thus, CD34
+ cells enriched by the immunoabsorption column were incubated with 20 l anti-CD34 MoAb (anti-HPCA2 epitope; Becton Dickinson, San Jose, CA, USA), conjugated with either FITC or PE at approximately 1 × 10 6 cells, for 30 min at 4°C in the dark, and then washed twice with PBS. The cells were then resuspended in RPMI-1640 and sorted with an appropriate gate to exclude cellular debris and aggregates. Flow cytometric separation was performed using EPICS-ELITE ESP Cell Sorter (Coulter, Hialeah, FL, USA) with data analysis performed by ELITE ESB workstation software. The purity of CD34 + cells separated by the two steps was Ͼ95% (Figure 1 ).
CFU-GM colony formation
Enriched or purified CD34 + cells were placed at 1 × 10 4 cell/ml in pre-prepared 0.9% methylcellulose contain- Leukemia ing Iscove's medium, 30% FBS, 1% bovine serum albumin, 10 −4 M ␤-mercaptoethanol and 2 mM L-glutamine (catalog No. HCG4230, Stem Cell Technologies). The concentration of the cytokine added was IL-3 100 U/ml, GM-CSF 50 ng/ml, or G-CSF 75 ng/ml or IL-6 50 ng/ml, which were found to be the optimal concentrations (data not shown). The culture mixtures were placed in 35 mm dishes (Irvine Scientific, Irvine, CA, USA) for 14 days at 37°C in a humidified incubator containing 5% CO 2 in air and colonies (Ͼ20 cells) were counted with an inverted microscope. Three dishes were plated for each experimental point. The CFU-GM score of each sample was obtained from the mean of the individual CFU-GMs in the triplicate dishes. When several samples were used for an experiment, the results were calculated as the mean ± s.d. of the triplicate means.
Analysis of differentiation
Differentiation was examined only on cells purified by two steps of CD34 + separation. The cells were placed at 10 5 cell/ml in liquid medium (catalog No. 430-220, GIBCO, Gaithersburg, MD, USA), containing 10% FBS (HyClone, Logan, UT, USA) and IL-3 100 U/ml in the presence or absence of 3 × 10 −7 M ATRA. IL-3 was included in the culture to maintain a similar culture condition as the colony formation growth assay. After 7 and 14 days, the cells were washed and analyzed for myeloid differentiation by NBT reduction after mixing 25 000 cells in 250 l PBS with an equal volume of a solution containing 0.2% NBT (Sigma) and 100 ng/ml of 12-O-tetradecanoylphorbol 13-acetate (TPA) for 25 min at 37°C. The cells were resuspended in 20 l of PBS, air-dried slides were prepared by cytospin, and stained with Leukostat staining kit (catalog No. CS-430D; Fisher, Pittsburgh, PA, USA). NBT reduction was detected by formation of blue-black formazan deposits in the cells. At least 200 cells were counted.
In addition, 14 day CFU-GM colonies grown in methylcellulose with IL-3 (with or without ATRA), were picked with a micropipette and the cells from each individual culture dish were pooled in PBS. The cells were washed and incubated for 25 min at 37°C in media with equal volume of 0.2% of NBT dissolved in PBS containing 100 ng of freshly diluted TPA per ml. The percentage of cells containing intracellular blueblack formazan deposits obtained from each individual culture dish was determined on leukostat cytospin slides. Each experimental point was set in two dishes and the results expressed as the mean of the duplicate.
Apoptosis assay
All apoptosis assays were performed on cells purified by the two steps of CD34 separation. The cells were placed at 10 5 cell/ml in liquid medium containing 10% FBS and IL-3 100 U/ml in the presence or absence of 3 × 10 −7 ATRA and samples were taken on days 7 and 14 of culture for analysis. IL-3 was included in the culture since cells undergo apoptosis when growth factors are withdrawn 32, 33 as well as to maintain similar culture condition to cell growth assay. Apoptosis was first assayed by flow cytometry binding of annexin V and propidium iodide (PI) using an Apoptosis Detection Kit (catalog No. KNX50, R & D Systems, Minneapolis, MN, USA). 34 During the early phase of apoptosis, before nuclear condensation had started, the cells exposed phosphatidylserine on the outer membrane which binds to annexin V. Cells with compromised membranes will allow PI to bind to cellular DNA. Live cells will not stain with either fluorochrome, necrotic cells will stain with both fluorochromes while cells undergoing apoptosis will stain only with annexin V. CD34
+ cells were washed with cold PBS and 1 × 10 5 cells per 100 l of binding buffer and mixed with 10 l FITC-conjugated annexin V (10 g/ml) and 10 l of PI (50 g/ml) for 15 min at room temperature. Flow cytometric analysis was performed using a FACSCAN flow cytometer (Becton Dickinson) with analysis by Consort 30 software. A second assay to identify apoptosis in individual cells was performed by the TUNEL (TdT-mediated dUTP-nick end labeling) in situ labeling of DNA fragmentation in the nucleus, using an Oncor Apoptag plus kit (catalogue No. 57101-KIT; Oncor, Gaithersburg, MD, USA), as previously described. 35 Briefly, the CD34 + cells were cytocentrifugated on glass slides, air-dried, fixed with 4% neutral buffered formaldehyde and washed with PBS. Endogenous peroxidase was quenched by adding 3% hydrogen peroxide for 5 min. Terminal deoxynucleotidyl transferase (TdT) enzyme was added to catalyze binding of digoxigeninnucleotide triphosphate to the 3Ј-OH ends at sites of DNA breaks. The slides were incubated with peroxidase-conjugated anti-digoxigenin and diaminobenzidene and counter stained with methylgreen. The high concentration of 3Ј-OH ends generated by DNA fragmentation are localized in morphological identifiable nuclei apoptotic bodies that are stained and can be visualized in situ.
Results
Effect of ATRA on CFU-GM colony formation from CD34
+ cells
The concentration of ATRA used in the experiments was 3 × 10 −7 M which was the optimal concentration for stimulating CFU-GM from unseparated bone marrow cells in our earlier report. 23 The following experiments were performed with CD34
+ enriched to 55-96% by the avidin-biotin immunoabsorption column.
Using the same eight bone marrow samples, each from a different donor, we found that ATRA significantly increased the number of CFU-GM colonies from all samples induced by IL-3 or GM-CSF compared to their respective control cultures without ATRA (P = 0.0004 and P = 0.008, respectively) ( Table   1 ). In contrast, the number of G-CSF-induced CFU-GM colonies did not increase in the presence of ATRA (Table 1 ). In the eight samples, the increment in the colony count by ATRA was significantly higher for IL-3-induced CFU-GM (mean ± s.d.: 3.25 ± 1.13-fold; range 1.93-5.63-fold) than for GM-CSF (2.17 ± 0.8-fold; range 1.43-3.5-fold), or for G-CSF colonies (1.06 ± 0.17-fold; range 0.71-1.25-fold) (analysis of variance P = 0.00012). The mean (± s.d.) number of CFU-GM in samples obtained from a group of 20 patients (including 12 patient samples studied only with IL-3) was 78 ± 47 colonies per 10 4 cells with IL-3 but without ATRA, and 214 ± 123 per 10 4 cells with IL-3 plus ATRA; the mean increment was 3.13 ± 1.17-fold (range 1.39-5.76). Sixteen of 20 (80%) samples showed a two-fold or more CFU-GM increment. In addition, in the presence of ATRA, the IL-3-induced colonies appeared larger in size than those that developed without ATRA. IL-6 did not induce CFU-GM colony formation either with or without ATRA ( Table 1) . In separate experiments, we demonstrated that the concentration of 3 × 10 −7 M of ATRA was optimal for its effect on colony formation employing the different cytokines (data not shown).
In the absence of ATRA the baseline number of colonies grown with G-CSF was much higher than with IL3 or GM-CSF. It is therefore possible that ATRA did not increase the number of G-CSF-induced colonies because the growth capability of CFU-GM colonies was saturated. To test this possibility we set two experiments to measure the effect of ATRA on colonies stimulated by the combination of G-CSF and IL-3. In the presence of ATRA, the number of colonies stimulated by G-CSF increased when IL-3 was added, indicating that the lack of ATRA effect on G-CSF induced colonies was not because the cultures had reached their maximal growth capacity (Table 2) .
ATRA alone in the absence of a cytokine in the culture, did not induce colonies from CD34 + enriched cells. In addition, only a very small number of IL-3-induced CFU-GM colonies grew from the column non-absorbed CD34
− cells in the presence or absence of ATRA (1.0 ± 0.6 and 4.1 ± 3.8 CFU-GM/10 4 cells, respectively). This CD34 − population contained a median of 1.3% (range 0.1-4.5%) CD34
+ cells which were most likely responsible for the few colonies which were observed.
In the above experiments, CD34 + cells were exposed to ATRA from the beginning of the culture. In the next set of experiments, we determined how long the developing CFU-GM colonies remained sensitive to the growth enhancing effect of ATRA, by adding ATRA to the top of the methylcellulose dishes after a delay of 1-13 days from the initiation of the cultures. Figure 2 shows that the enhancing effect on IL-3-or GM-CSF-induced colonies was maximal when ATRA was added on the 2nd day of the culture, and then gradually decreased as the addition of ATRA was delayed. By adding ATRA to the cultures after more than 9-10 days, the number of colonies no longer increased compared to cultures without ATRA. ATRA had no significant effect on G-CSF-induced colonies when added at any time interval (Figure 2) .
In order to determine if ATRA had a direct effect on CD34 + cells, we further enriched the column immunoabsorbed CD34 + cells to a purity of greater than 95% by a second purification step using flow cytometry sorting to remove almost all potential accessory non-CD34
+ cells. Figure 3 shows a slight drop in colony growth in the more purified cells, but the degree of enhancement by ATRA was similar (mean ± s.d. 3.6 ± 1.1-fold) when compared to that obtained after the first step of CD34 + cell enrichment (3.2 ± 1.4-fold). CD34 + cells were separated by the immunoabsorption column (first-step separation) and incubated with or without 3 × 10 −7 M ATRA and the respective cytokine. CFU-GM colonies were counted after 14 days in culture. The same eight patient samples were used. The results are expressed as number of colonies per 1 × 10 4 CD34 + cells. Each sample was plated in three dishes. The CFU-GM score of each sample was obtained from the mean of the individual CFU-GMs in the triplicate dishes. With several samples for each experimental point the results were calculated as the mean ± s.d. of the triplicate means of each sample. ⌬ ± ATRA: the ratio between the number of colonies with and without ATRA calculated first for each sample and then the mean of the samples is recorded. 
Effect of ATRA on myeloid differentiation of CD34
+ cells Using CD34 + cells purified to Ͼ95% after the two separation steps, we measured myeloid differentiation by the ability to reduce NBT by production of superoxide. After 7 days in liquid medium in the presence of IL-3, the number of NBTpositive cells was similar with or without ATRA. After 14 days, the number of NBT positive cells was significantly higher in the cultures containing ATRA (Table 3) . To further evaluate differentiation, seven to 10 individual 14-day CFU-GM colonies were picked and pooled from each individual culture plate and stained with BMT. In two separate experiments with IL-3, 80% and 83% of the cells in the colonies grown with ATRA were NBT positive, compared to 43% and 58%, respectively, of the cells in the colonies without ATRA.
Effect of ATRA on apoptosis of CD34
Employing CD34 + cells purified to Ͼ95% after the two separation steps, we measured apoptosis by two methods. Using binding of annexin V, 5.1% of the total cells cultured for 14 days with IL-3 were apoptotic, while the proportion of the apoptotic cells increased to 17.1% with addition of 3 × 10
of ATRA. Using the in situ method, the percentage of apoptotic cells after 14 days in cultures with IL-3 and without ATRA was relatively low but it markedly increased when ATRA was Leukemia added to the culture (Table 4) . Of note, higher percentages of apoptotic cells were detected in the IL-3 plus ATRA cultures by the in situ assay than by the annexin V method. A smaller increase in the percentage of apoptotic cells was also seen by the in situ method in day 7 cultures with IL-3 plus ATRA when compared to cultures with IL-3 alone (Table 4) .
Discussion
In this study, we further characterized the effect of pharmacological ATRA concentrations on normal human enriched and purified CD34
+ hematopoietic progenitor cells. We limited the experiments to studying myeloid progenitors using only the CFU-GM assay. The results confirmed our previous observations 23 with unfractionated bone marrow cells, that ATRA, in the presence of colony-stimulating factors, increases in vitro the number of CFU-GM colonies. We also confirmed with CD34 + enriched cells, that ATRA itself does not act as a colony-stimulating factor, and does not induce colony formation in the absence of a cytokine. For example, using IL-6, which by itself does not stimulate colony growth, ATRA was unable to induce CFU-GM. Thus, myeloid progenitors probably must first be stimulated to grow by an appropriate cytokine before ATRA can stimulate further proliferation. The effect of ATRA is directly on CD34 + cells, and not mediated through accessory cells, since the stimulating effect was not reduced when the CD34 + purity was increased from an average of 79% to greater than 95%. Similarly, previous observations with unfractionated bone marrow cells demonstrated that removal of mononuclear cells did not change the enhanced colony growth with ATRA. 23, 26 Utilizing molecularly defined cytokines, we demonstrated that the enhancing effect of ATRA on myeloid progenitors is dependent on the type of cytokine employed. The greatest effect was seen with IL-3, slightly less enhancement with GM-CSF, but no enhancement by ATRA in colonies induced by G-CSF. Tohda et al, 36 using unfractionated bone marrow cells, also reported that ATRA stimulated CFU-GM induced by IL-3 or GM-CSF but inhibited colonies grown with G-CSF. In the only other study using CD34 + purified cells stimulated by individual cytokines reported by Smeland et al, 37 in which only two cell samples were employed, ATRA enhanced GM-CSFinduced CFU-GM colonies while it inhibited the growth of G-CSF-induced colonies; IL-3 was not examined. Taken together, the differential effect of the three individual cytokines, IL-3, GM-CSF, and G-CSF on ATRA modulation of myeloid progenitor growth appears similar in the three studies. 36, 37 We were also able to show that this is a consistent phenomenon, verified on samples from multiple subjects. These results suggest a relationship between ATRA growth stimulation and the cytokine-responding target cells. IL-3 and GM-CSF stimulate the growth of overlapping but less mature CFU-GM, while G-CSF stimulates more differentiated myeloid progenitors. 38, 39 The ATRA enhancing activity on CFU-GM grown with IL-3 and GM-CSF and lack of effect with G-CSF, probably implies that the target cells for ATRA growth stimulation are less mature IL-3 and GM-CSF-responding myeloid progenitors but not the more mature G-CSF-responding progenitor cells. Our time-delayed experiments support this possibility by showing that the enhancing activity of ATRA was maximal when the compound was added early in the course of the culture, while the colonies were still at their early stages of maturation. The response progressively declined as the addition of ATRA was delayed, and was no longer observed after the colonies had passed a certain degree of development. Thus, the growth enhancing activity of pharmacological levels of ATRA appears to be limited to a relatively early stage of the myeloid progenitor maturation and disappears as the cells differentiate.
The mechanism whereby ATRA increases the number of normal CFU-GM in culture is not clear. It is unlikely that newly formed cells within the developing colonies would serve as accessory cells providing additional growth factors, since our time-delayed experiments showed that the effect of ATRA diminishes as the colony increases in size. It is possible that ATRA stimulates the recruitment of additional preformed myeloid progenitors that otherwise die, to form colonies by 0  0  100  0  0  100  0  Sample 1  7  33  34  14  70  308  215  95  416  395   Sample 2  7  39  40  14  37  185  69  91  180  163 100 000 CD34 + cells that were separated by immunoabsorption column and flow cytometry sorting (two steps) and incubated for 7 and 14 days in 2 ml liquid medium with 100 U/ml IL-3 and with or without 3 × 10 CD34 + cells that were separated by immunoabsorption followed by flow cytometry sorting (two steps) were incubated in liquid medium with 100 U/ml IL-3 and with or without 3 × 10 −7 M ATRA. The results represent the percentage of cells staining positive with peroxidaseconjugated anti-digoxigenin demonstrating in situ apoptosis after 7 and 14 days in culture (two experiments).
increasing their sensitivity to IL-3 and GM-CSF. An alternative possibility that ATRA shifts less mature multi-lineage progenitors towards a myeloid program of differentiation was not studied, and would require assays of multipotent progenitors. However, Tocci et al 30 showed with a mixture of cytokines and erythropoietin that ATRA shifts the differentiation of human fetal liver CD34 + cells from an erythroid/monocytic pathway towards the granulocytic lineage.
All-trans retinoic acid also intervenes in the programmed cell death and differentiation of CD34 + . In our experiments, IL-3 prevention of apoptosis 32, 33 was reversed and CD34 + cells died by programmed cell death, when ATRA was added to the cultures with IL-3. Similarly, Josefsen et al 40 described that ATRA opposed the anti-apototic activities of GM-CSF and G-GSC on CD34 + . A dual effect of growth stimulation and apoptosis as seen with IL-3 and GM-CSF on CD34 + , has also been described in the development of other organs. 41, 42 In addition, our study showed that normal human CD34 + cells differentiate by ATRA and IL-3 to granulocytes capable of reducing NBT. Although not directly studied, it is possible that the growth and differentiation effect of ATRA are coupled as suggested for hematopoietic cells by several investigators. 43, 44 Our experiments also show in CD34
+ cells incubated with IL-3, that ATRA induces granulocytic differentiation in parallel with programmed cell death, a phenomenon which has been Leukemia observed in other cell systems. For example, in the p19 mouse embryonal carcinoma cell line, ATRA induces differentiation toward neuronal cells in association with cellular apoptosis. 45, 46 Also, the myeloid leukemia HL-60 cell line differentiates with ATRA to granulocyte-like cells 5 together with cellular apoptosis. 47, 48 Our in vitro experiments were limited to pharmacological concentrations of ATRA in the presence of individual cytokines and further confirm that this drug has biological activities on hematopoietic cells of the myeloid-lineage that have normal nuclear retinoid receptors. The in vivo correlates of the culture results are not clear. In general, clinical trials studying ATRA in cancer have not reported changes in neutrophil counts 49 except for leukocytosis in anecdotal cases 50 and in more than half of active acute promyelocyic leukemia (APL) cases. 51 It is possible, that in bone marrow of non-APL cancer patients an in vivo stimulatory effect of ATRA on the small numbers of normal myeloid progenitors is counterbalanced by other opposing mechanisms and does not become clinically apparent. In contrast, APL patients with active disease often exhibited a dramatic hyperleukocytosis while being treated with ATRA. 51 The rise in circulating leukemic cells is seen early in the course of treatment and returns to baseline with continuation of ATRA administration and further differentiation of the leukemic cells. Interestingly, APL patients in complete remission, that have few or no leukemic cells, do not exhibit leukocytosis while receiving ATRA as maintenance treatment. 13 In active APL, the bone marrow is essentially replaced by a homogenous population of malignant cells and it is possible that a potential in vivo effect of ATRA on their growth can be clinically expressed. We are speculating that the clinical hyperleukocytosis observed in APL patients during early ATRA administration, is reminiscent of the in vitro activity of ATRA on normal myeloid progenitors; growth enhancement of immature APL cells that subsequently undergo apoptosis with further differentiation.
